LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study

Qing Zhou(Jiangnan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Liang Sun(Nanchang University), Da Huang(Nanchang University), Yanping Hu(Chinese People's Liberation Army), Megan Zhao(University of Pennsylvania), Yaqi Shen, Meili Sun(Jinan Central Hospital), Jingjing Huang(Second Affiliated Hospital of Nanjing Medical University), Jun Lin(Soochow University), Xue Meng(Shandong First Medical University), R-H. Guo(Jiangsu Province Hospital), Jing Shan, Wu Zhuang(Hunan University), Yan Yu(Binzhou Medical University), C. Xu(Guangdong Academy of Medical Sciences), Yueyin Pan(University of Science and Technology of China), Ning Yang(Soochow University), Mengna Huang(Brigham and Women's Hospital)
Annals of Oncology
November 1, 2023
10.1016/j.annonc.2023.10.584
Cited by 10

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k